Associated Papers
Discovery of a MET -driven monogenic cause of steatotic liver disease.
Pinto E Vairo F et al.
Hepatology (baltimore, Md.), 2025
Conserved regulatory motifs in the juxtamembrane domain and kinase N-lobe revealed through deep mutational scanning of the MET receptor tyrosine kinase domain.
Estevam GO et al.
Elife, 2024
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors.
Pecci F et al.
Cancer Discovery, 2024
38564707 (PubMed )
Supplement: cd-23-1217_supplementary_table_2_suppst2.pdf
Conserved regulatory motifs in the juxtamembrane domain and kinase N-lobe revealed through deep mutational scanning of the MET receptor tyrosine kinase domain.
Estevam GO et al.
Biorxiv : the Preprint Server for Biology, 2024
Biophysical and structural characterization of the impacts of MET phosphorylation on tepotinib binding.
Grädler U et al.
The Journal of Biological Chemistry, 2023
37806493 (PubMed )
Supplement: mmc3.pdf
Discovery and Pharmacokinetic and Pharmacological Properties of the Potent and Selective MET Kinase Inhibitor 1-{6-[6-(4-Fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-3-ylsulfanyl]benzothiazol-2-yl}-3-(2-morpholin-4-ylethyl)urea (SAR125844).
Ugolini A et al.
Journal of Medicinal Chemistry, 2016
27355974 (PubMed )
Supplement: jm6b00280_si_001.pdf
EGF receptor activates MET through MAPK to enhance non-small cell lung carcinoma invasion and brain metastasis.
Breindel JL et al.
Cancer Research, 2013
Regulation of the wild-type and Y1235D mutant Met kinase activation.
Cristiani C et al.
Biochemistry, 2005
Mutations in the met oncogene unveil a "dual switch" mechanism controlling tyrosine kinase activity.
Chiara F et al.
The Journal of Biological Chemistry, 2003
Tyrosine 1356 in the carboxyl-terminal tail of the HGF/SF receptor is essential for the transduction of signals for cell motility and morphogenesis.
Zhu H et al.
The Journal of Biological Chemistry, 1994
Select a paper to view details